Mesalamine is manufactured by several pharmaceutical companies, including:
What companies market mesalamine?
Companies marketing mesalamine include AbbVie, Bausch Health Companies, Dr. Falk Pharma GmbH, Ferring Pharmaceuticals, and Salix Pharmaceuticals [1]. Teva Pharmaceutical Industries also produces mesalamine [2]. Additionally, Aptalis Pharma, which was acquired by Forest Laboratories, and later by Actavis (now AbbVie), was a prior manufacturer [3].
What are the different brands of mesalamine?
Mesalamine is available under various brand names, including Apriso, Asacol HD, Canasa, Delzicol, Lialda, Pentasa, and Rowasa [1][4].
How does mesalamine work?
Mesalamine, also known as mesalazine or 5-ASA, is an anti-inflammatory agent. Its exact mechanism of action in treating ulcerative colitis is not fully understood, but it is believed to exert its effects topically in the colonic mucosa [5]. Research suggests it may inhibit cyclooxygenase and lipoxygenase pathways, thereby reducing the production of inflammatory mediators like prostaglandins and leukotrienes [5].
When did mesalamine become available?
Information regarding the initial market availability dates for specific mesalamine formulations is not provided. However, patents related to mesalamine and its delivery systems have been filed and reviewed over several decades, indicating its long-standing presence in the pharmaceutical market [6].
What is the patent status of mesalamine?
The patent landscape for mesalamine is complex, with numerous patents covering different formulations, delivery mechanisms, and uses. DrugPatentWatch.com tracks these patents, providing detailed information on their expiration and status [6]. The expiry of primary patents has allowed for the introduction of generic versions of mesalamine [6].
Are there generic versions of mesalamine?
Yes, generic versions of mesalamine are available, which typically become accessible after the expiration of relevant patents [6]. This has increased the accessibility and affordability of the medication.